Press release
Aleva Neurotherapeutics Receives CE Mark for its directSTIM™ Deep Brain Stimulation System and Raises USD 8 Million Private Equity
Lausanne, Switzerland, December 16, 2019 – Aleva Neurotherapeutics, a leading developer of implants for deep brain stimulation (DBS) in major neurological indications such as Parkinson’s disease and essential tremor, today announced that it has been awarded the CE Mark for its flagship product, the directSTIMTM Deep Brain Stimulation System.Aleva’s revolutionary DBS system incorporates directional electrode technology and is designed to be more precise and efficient, with optimized stimulation that will potentially reduce side effects. At present, Aleva is the only emerging technology company to be awarded the CE-Mark for Deep Brain Stimulation. The Company will initiate direct sales through a post-market clinical follow-up study in select European neurological clinics.
The Company also announced it has raised USD 8 million in a first closing of a Series E financing round from existing and undisclosed new private investors. A limited additional amount of the round remains open to qualified investors. With its European market entry secured, the Company will now drive its efforts towards US market entry. The Company has been riding a wave of momentum driven by the uniqueness of its core technology and the major unmet needs in treating neurological disorders. Previously, the successful results of Aleva’s directSTN pilot study were published in Brain (DOI: 10.1093/brain/awu102) and strongly suggested the potential of directional stimulation in improving surgical outcomes. Earlier this year, Aleva announced the successful creation and funding of a joint venture with Dixi Medical SAS named Adept Neuro SA that aims to achieve regulatory approval for its core technology in the field of epilepsy surgery.
"The CE Mark is a significant milestone in Aleva´s development. Our Deep Brain Stimulation System incorporates first-in-class directional electrode technology with an easy-to-use patient programming interface that will enable functional neurosurgery teams to provide better outcomes for their patients. We have demonstrated that we can achieve and maintain technological leadership in our field, and we are now ready to expand our market in Europe while remaining focused on the US FDA regulatory process," said André Mercanzini PhD, CEO of Aleva Neurotherapeutics.
###
Contact:
Aleva Neurotherapeutics
EPFL Innovation Park, Building D
CH - 1015 Lausanne
Switzerland
André Mercanzini, PhD
CEO
andre.mercanzini@aleva-neuro.com
Media Inquiries:
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info(at)akampion.com
Tel. +49 40 88 16 59 64 or +49 30 23 63 27 68
About Aleva Neurotherapeutics
Aleva Neurotherapeutics is a spin-off from the Swiss Federal Institute of Technology in Lausanne (EPFL) Microsystems Laboratory of Prof. Philippe Renaud. Aleva Neurotherapeutics has so far raised over USD 50 million from renowned institutional investors, among them Forrestal Capital, Kinled Holding, BioMedPartners (through its BioMedInvest-II LP Fund), BB Biotech Ventures LP, Kreaxi and Initiative Capital Romandie, as well as from select private investors.
For more information, visit: www.aleva-neuro.com
About Deep Brain Stimulation
Deep brain stimulation (DBS) is approved worldwide for the treatment of Parkinson’s disease (PD), essential tremor, dystonia, obsessive-compulsive disorder (OCD) and epilepsy. It is also under investigation for the treatment of a number of other conditions, including major depression. DBS is a therapy that relies on the delivery of mild electrical pulses to specific areas in the brain via an implanted lead connected to a battery-powered pulse generator placed in the patient’s upper chest area. A physician is able to vary and control the stimulation delivered through the lead to the brain using an external, hand-held programmer. At present, DBS systems use leads with electrodes that send out electrical current in all directions, which can result in unwanted
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Aleva Neurotherapeutics Receives CE Mark for its directSTIM™ Deep Brain Stimulation System and Raises USD 8 Million Private Equity here
News-ID: 1879682 • Views: …
More Releases from Aleva Neurotherapeutics
Aleva Neurotherapeutics Raises CHF 4.0 Million in Series B Financing Round
- Lead investor Banexi Ventures Partners joins strong investment consortium -
Lausanne, Switzerland, April 10, 2012 – Aleva Neurotherapeutics, a company developing next-generation implants for Deep Brain Stimulation (DBS) in major neurological indications such as Parkinson´s disease or depression, today announced the closing of a Series B financing round totaling CHF 4.0 million.
Banexi Ventures Partners acted as a lead investor in the financing, with selected private investors also participating in…
Aleva Neurotherapeutics Expands Board of Directors
- Entrepreneur Martin Velasco and Industry Expert Scott R. Ward Appointed as Board Members -
Lausanne, Switzerland, March 20, 2012 – Aleva Neurotherapeutics, a company developing next-generation implants for Deep Brain Stimulation (DBS) in major neurological indications such as Parkinson´s disease or depression, today announced the expansion of its Board of Directors. Martin Velasco, a seasoned entrepreneur and business angel, and Scott R. Ward, advisor and former Senior Vice President and…
More Releases for Neuro
Global Neuro-stimulators Market By Type (Invasive Neuro-stimulators, Non-invasiv …
The Global Neuro-stimulators Market 2020 report implement in-depth research of the industry with a focus on the current market trends future prospects. The Global Neuro-stimulators Market report aims to provide an overview of Neuro-stimulators Market players with detailed market segmentation by product, application and geographical region. It also provides market share and size, revenue forecast, growth opportunity. The most recent trending report Worldwide Neuro-stimulators Market Economy by Manufacturers, Regions, kind…
Neuro Ablation Devices Market Professional Survey Report 2018
Neuro ablation devices are medical devices that are applied to iatrogenic Peripheral Nerve Injury (PNI). A peripheral nerve is composed of axon, myelin, endoneurium, fascicle, perineurium and epineurium. The individual myelinated axons and groups of unmyelinated axons are usually surrounded by the endoneurium. Currently available neuro ablation devices focus on precise and target-oriented denervation. Recurrence of pain after a short period is always a problem in pain practice. Recurrence of…
Peripheral Nerve Stimulators Market || Key Player - Stim wave LLC, Neuro Sigma I …
Market Research Reports Search Engine (MRRSE) has recently updated its massive report catalogue by adding a fresh study titled “Peripheral Nerve Stimulators Market Industry Development Scenario and Forecast to 2026”. This business intelligence study encapsulates vital details about the market current as well as future status during the mentioned forecast period of 2026.The report also targets important facets such as market drivers, challenges, latest trends, and opportunities associated to growth…
Neuro-Endoscopy Market Size, Share, Development by 2023
New report published by Market Research Report Store (MRRS) which offers insights on the global Neuro-Endoscopy market.
Neuro-Endoscope is an endoscope for examining and performing various interventions in the central nervous system.
Neuro-endoscopy enterprises are mainly concentrated in Europe, Japan, and United States. Rudolf, B.Braun, Carl Storz and Richard Wolf are the major players in the industry. And they account for more than 50% of the market share.
Click…
Neuro-navigation Systems Market - Size, Share, Outlook
Rising adoption of minimally invasive surgical procedures is expected to fuel growth of the neuro-navigation systems market. Moreover, increasing number of neurological surgeries performed worldwide is also expected to drive demand for neuro-navigation market. According to the AANS National Neurosurgical Procedural Statistics, in 2011, neurosurgeons performed 2,296,331 total procedures, 1,448,400 of which were spine surgeries in the U.S. Rise in number of people suffering with brain tumor and cancer leading…
Neuro Critical Care Market Future Opportunities 2024
The branch of medicines concerned with life threatening illnesses or injuries of brain is called as Neuro critical care or intensive care. The head or physical trauma of brain are called as traumatic brain injury (TBI). The traumatic brain injury are occurred when there is injury in brain. The brain injury can cause internal damage to the brain parts or skull fracture. Trauma center are intensive care unit or neuro…
